Kenvue beats profit forecast and increases sales outlook, stock up 6.30%

From Yahoo Finance: 2025-05-08 17:19:00

Consumer health company Kenvue Inc. reported first-quarter 2025 sales of $3.74 billion, surpassing the consensus of $3.68 billion. Sales decreased 3.9% year over year, with a 1.2% organic sales decline. Iconic brands like Aveeno and Tylenol are part of Kenvue’s portfolio. Gross profit margin was 58.0%, up from 57.6% last year. Operating income margin was 14.9%. The self-care segment recorded $1.67 billion in net sales, while the skin health segment saw a 7% drop. Kenvue updated its fiscal 2025 outlook, with net sales expected to increase by 1% to 3%. The company also announced a new CFO and a five-year collaboration with Microsoft to enhance digital operations through AI technologies. KVUE stock is up 6.30% at $24.57.



Read more at Yahoo Finance: Neutrogena-Maker Kenvue Beats Profit Forecast, Ups Sales Outlook (UPDATED)